Literature DB >> 25673304

H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.

Tao Qin1, Yinyan Yin1, Lulu Huang1, Qinghua Yu1, Qian Yang2.   

Abstract

Influenza whole inactivated virus (WIV) is more immunogenic and induces protective antibody responses compared with other formulations, like split virus or subunit vaccines, after intranasal mucosal delivery. Polyethyleneimine (PEI), an organic polycation, is widely used as a reagent for gene transfection and DNA vaccine delivery. Although PEI recently has demonstrated potent mucosal adjuvant activity for viral subunit glycoprotein antigens, its immune activity with H9N2 WIV is not well demonstrated. Here, mice were immunized intranasally with H9N2 WIV combined with PEI, and the levels of local respiratory tract and systemic immune responses were measured. Compared to H9N2 WIV alone, antigen-specific IgA levels in the local nasal cavity, trachea, and lung, as well as levels of IgG and its subtypes (IgG1 and IgG2a) in the serum, were strongly enhanced with the combination. Similarly, the activation and proliferation of splenocytes were markedly increased. In addition, PEI is superior as an H9N2 WIV delivery system due to its ability to greatly increase the viral adhesion to mucosal epithelial cells and to enhance the cellular uptake and endosomal escape of antigens in dendritic cells (DCs) and further significantly activate DCs to mature. Taken together, these results provided more insights that PEI has potential as an adjuvant for H9N2 particle antigen intranasal vaccination.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25673304      PMCID: PMC4375346          DOI: 10.1128/CVI.00778-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  37 in total

Review 1.  Nasal drug delivery--possibilities, problems and solutions.

Authors:  Lisbeth Illum
Journal:  J Control Release       Date:  2003-02-21       Impact factor: 9.776

2.  CTL induction by cross-priming is restricted to immunodominant epitopes.

Authors:  Viktor Pavelic; Matthias S Matter; Sabine Mumprecht; Isabel Breyer; Adrian F Ochsenbein
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

3.  In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery.

Authors:  C Witschi; R J Mrsny
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

Review 4.  Design and gene delivery activity of modified polyethylenimines.

Authors:  R Kircheis; L Wightman; E Wagner
Journal:  Adv Drug Deliv Rev       Date:  2001-12-31       Impact factor: 15.470

5.  Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice.

Authors:  Inez M van der Lubben; Gideon Kersten; Marjan M Fretz; Coen Beuvery; J Coos Verhoef; Hans E Junginger
Journal:  Vaccine       Date:  2003-03-28       Impact factor: 3.641

6.  Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.

Authors:  Sandra S Diebold; Tsuneyasu Kaisho; Hiroaki Hemmi; Shizuo Akira; Caetano Reis e Sousa
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

7.  Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses.

Authors:  K L Hartshorn; E C Crouch; M R White; P Eggleton; A I Tauber; D Chang; K Sastry
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

8.  Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments.

Authors:  A F Kotzé; H L Luessen; A G de Boer; J C Verhoef; H E Junginger
Journal:  Eur J Pharm Sci       Date:  1999-01       Impact factor: 4.384

9.  Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration.

Authors:  Niels Hagenaars; Enrico Mastrobattista; Rolf J Verheul; Imke Mooren; Harrie L Glansbeek; Jacco G M Heldens; Han van den Bosch; Wim Jiskoot
Journal:  Pharm Res       Date:  2009-02-18       Impact factor: 4.200

10.  Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

Authors:  Felix Geeraedts; Nadege Goutagny; Veit Hornung; Martina Severa; Aalzen de Haan; Judith Pool; Jan Wilschut; Katherine A Fitzgerald; Anke Huckriede
Journal:  PLoS Pathog       Date:  2008-08-29       Impact factor: 6.823

View more
  13 in total

1.  Bacillus amyloliquefaciens SQR9 induces dendritic cell maturation and enhances the immune response against inactivated avian influenza virus.

Authors:  Lulu Huang; Tao Qin; YinYan Yin; Xue Gao; Jian Lin; Qian Yang; Qinghua Yu
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

2.  Responses of primary human nasal epithelial cells to EDIII-DENV stimulation: the first step to intranasal dengue vaccination.

Authors:  Nattika Nantachit; Panya Sunintaboon; Sukathida Ubol
Journal:  Virol J       Date:  2016-08-18       Impact factor: 4.099

3.  Crosstalk between H9N2 avian influenza virus and crypt-derived intestinal organoids.

Authors:  Lulu Huang; Qihang Hou; Lulu Ye; Qian Yang; Qinghua Yu
Journal:  Vet Res       Date:  2017-11-02       Impact factor: 3.683

Review 4.  Polyethylenimine-based micro/nanoparticles as vaccine adjuvants.

Authors:  Chen Shen; Jun Li; Yi Zhang; Yuce Li; Guanxin Shen; Jintao Zhu; Juan Tao
Journal:  Int J Nanomedicine       Date:  2017-07-31

5.  Histological and anatomical structure of the nasal cavity of Bama minipigs.

Authors:  Jingjing Yang; Lei Dai; Qinghua Yu; Qian Yang
Journal:  PLoS One       Date:  2017-03-24       Impact factor: 3.240

6.  Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application.

Authors:  Jacqueline M Lankelma; Alex Wagemakers; Emma Birnie; Bastiaan W Haak; Jos J A Trentelman; Tassili A F Weehuizen; Jasmin Ersöz; Joris J T H Roelofs; Joppe W Hovius; W Joost Wiersinga; Adriaan D Bins
Journal:  Virulence       Date:  2017-04-19       Impact factor: 5.882

Review 7.  Noninvasive vaccination against infectious diseases.

Authors:  Zhichao Zheng; Diana Diaz-Arévalo; Hongbing Guan; Mingtao Zeng
Journal:  Hum Vaccin Immunother       Date:  2018-05-17       Impact factor: 3.452

8.  Use of Proteins Identified through a Functional Genomic Screen To Develop a Protein Subunit Vaccine That Provides Significant Protection against Virulent Streptococcus suis in Pigs.

Authors:  Susan L Brockmeier; Crystal L Loving; Tracy L Nicholson; Jinhong Wang; Sarah E Peters; Lucy Weinert; Roy Chaudhuri; David J Seilly; Paul R Langford; Andrew Rycroft; Brendan W Wren; Duncan J Maskell; Alexander W Tucker
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

9.  Inhibition of H9N2 Virus Invasion into Dendritic Cells by the S-Layer Protein from L. acidophilus ATCC 4356.

Authors:  Xue Gao; Lulu Huang; Liqi Zhu; Chunxiao Mou; Qihang Hou; Qinghua Yu
Journal:  Front Cell Infect Microbiol       Date:  2016-10-25       Impact factor: 5.293

10.  Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.

Authors:  Hanmei Li; Yanping Li; Xue Wang; Yingying Hou; Xiaoyu Hong; Tao Gong; Zhirong Zhang; Xun Sun
Journal:  Theranostics       Date:  2017-09-26       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.